Metformin: do we finally have an anti-aging drug?

Area of Science:

• Gerontology and oncology research.
• Metabolic and signaling pathway studies.

Background:

• Hyperglycemia and hyperinsulinemia are linked to aging and cancer in mammals.
• Insulin/insulin-like signaling pathway inactivation extends lifespan across species.
• Caloric restriction's life-prolonging effects involve reduced insulin, IGF-1, and glucose.

Purpose of the Study:

• To explore the potential of antidiabetic biguanides to increase human lifespan.
• To investigate if biguanides' anti-aging and anti-cancer effects in rodents translate to humans.

Main Methods:

• Review of existing studies on mammals, nematodes, fruit flies, and rodents.
• Analysis of biguanide mechanisms, including insulin resistance reduction.
• Extrapolation of findings from animal models to human health.

Main Results:

• Biguanides like metformin reduce hyperglycemia and hyperinsulinemia.
• These drugs have demonstrated lifespan extension and cancer inhibition in rodents.
• Inactivation of insulin signaling pathways is a conserved mechanism for lifespan extension.

Conclusions:

• Antidiabetic biguanides show promise for increasing human lifespan.
• Further clinical studies are needed to confirm the life-prolonging and anti-carcinogenic effects of biguanides in humans.
• Targeting insulin/IGF-1 signaling pathways represents a potential therapeutic strategy for aging and cancer.